Table 3. Multivariate analyses of prognostic factors for overall survival in whole AML and non-M3 AML cases.
| Covariates | whole AML | non-M3 AML | ||
|---|---|---|---|---|
| Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | |
| Sex | 1.246 (0.688–2.257) | 0.467 | 1.360 (0.764–2.423) | 0.296 |
| Age | 1.346 (0.724–2.501) | 0.347 | 1.205 (0.614–2.364) | 0.588 |
| WBC | 1.591 (0.966–2.623) | 0.068 | 1.406 (0.839–2.358) | 0.196 |
| HB | 0.889 (0.355–2.225) | 0.801 | 0.862 (0.323–2.305) | 0.768 |
| PLT | 1.132 (0.535–2.393) | 0.746 | 1.159 (0.551–2.439) | 0.697 |
| Karyotype classifications | 4.049 (1.942–8.439) | 0.000 | 3.119 (1.113–8.738) | 0.030 |
| BMI1P1 expression | 0.462 (0.243–0.879) | 0.019 | 0.483 (0.254–0.919) | 0.027 |
| FLT3 mutation | 0.645 (0.299–1.393) | 0.265 | 0.654 (0.263–1.625) | 0.360 |
| NPM1 mutation | 1.967 (0.837–4.622) | 0.121 | 1.473 (0.665–3.261) | 0.340 |
| C/EBPA mutation | 0.634 (0.274–1.468) | 0.287 | 0.665 (0.280–1.582) | 0.357 |
| C-KIT mutation | 1.876 (0.243–14.462) | 0.546 | 4.037 (0.519–31.406) | 0.183 |
| IDH1 and IDH2 mutation | 7.663 (2.177–26.982) | 0.002 | 10.512 (2.914–37.916) | 0.000 |
| DNMT3A mutation | 0.730 (0.276–1.930) | 0.526 | 0.783 (0.290–2.111) | 0.629 |
| U2AF1 mutation | 1.727 (0.510–5.848) | 0.380 | 2.334 (0.702–7.758) | 0.166 |